No Title Author Volume Page
1 [SPECIAL ISSUE]Two years of COVID-19 pandemic: where are we now? Jinjong Myoung* vol.60,No.3,2022 235-237
2 Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies Jung-ah Choi and Jae-Ouk Kim* vol.60,No.3,2022 238-246
3 Current status and perspectives on vaccine development against dengue virus infection Jisang Park1,2, Ju Kim3, and Yong-Suk Jang1,2,3* vol.60,No.3,2022 247-254
4 Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models Young-Il Kim1, Mark Anthony B. Casel2, and Young Ki Choi1,2* vol.60,No.3,2022 255-267
5 Protective and pathogenic role of humoral responses in COVID-19 Uni Park1,2 and Nam-Hyuk Cho1,2,3* vol.60,No.3,2022 268-275
6 T cell responses to SARS-CoV-2 in humans and animals Sameer-ul-Salam Mattoo and Jinjong Myoung* vol.60,No.3,2022 276-289
7 SARS-CoV-2-mediated evasion strategies for antiviral interferon pathways Soo-Jin Oh and Ok Sarah Shin* vol.60,No.3,2022 290-299
8 Coordinated regulation of interferon and inflammasome signaling pathways by SARS-CoV-2 proteins Na-Eun Kim and Yoon-Jae Song* vol.60,No.3,2022 300-307
9 Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines Heedo Park, Mee Sook Park, Jong Hyeon Seok, Jaehwan You, Jineui Kim, Jeonghun Kim, and Man-Seong Park* vol.60,No.3,2022 308-320
10 COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity Mi-Hyun Lee1,2 and Bum-Joon Kim1,2,3* vol.60,No.3,2022 321-334
11 Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2 Chulwoo Kim1, Jae-Deog Kim2,3, and Sang-Uk Seo2,3* vol.60,No.3,2022 335-346
12 Coronavirus enzyme inhibitors-experimentally proven natural compounds from plants Junsoo Park*, Rackhyun Park, Minsu Jang, Yea-In Park, and Yeonjeong Park vol.60,No.3,2022 347-354